Research Site

Hospitalet deLlobregat 08907

2 studies enrolling now · 11 studies all time

What they study most

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck, Advanced or Metastatic Non-Small Cell Lung Cancer, Breast Cancer, Breast Neoplasms, Locally Advanced Cervical Cancer, Ovarian Neoplasm, Ovarian Neoplasms, Progressive Metastatic Castrate-Resistant Prostate Cancer, Triple Negative Breast Neoplasms

Studies at this site

• Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) — Recruiting now
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) — Recruiting now
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer — Running, not enrolling
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy — Running, not enrolling
• Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer — Running, not enrolling
• Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck — Completed
• Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC — Running, not enrolling
• Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer — Completed
• A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. — Completed
• Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer — Completed
• Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer — Completed